Baird Medical Investment Holdings Ltd Ordinary Share (BDMD)

FairStock Score: 42/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the business. Baird Medical sells microwave ablation devices and needles in China, a niche medical-device area with potential as cancer and benign-tumor treatments grow. But potential is not a moat. The figures show negative earnings: the FairStock-calculated P/E is -1.25, ROE is -46.03%, and ROCE is -11.88%. That tells me the operation is consuming rather than producing owner earnings. The Piotroski F-Score of 1/9 is a red flag on financial strength, and the Altman Z-Score of 1.36 sits in the distress zone. Debt-to-equity of 0.54 is not overwhelming, but with losses, leverage matters. On valuation, the stock closed at $0.69 on 2026-10-13, near the 52-week low of $0.66 and far below the high of $3.70. FairStock's P/B of 0.45 suggests the market values the equity at less than half its book value. If the book value is real and the losses are temporary, that could be a classic Graham bargain. But there are zero years of filed results for Lynch classification, and revenue and profit growth are listed as N/A, so growth is unproven. The FairStock Score of 42/100 does not offset the red flags. A negative beta of -1.16 may diversify, but it does not fix poor operating economics. My conclusion: the price looks statistically cheap against assets, but business quality and financial health are too weak to call it a safe value opportunity. I would need evidence of improving earnings and a longer track record before taking the figures seriously.

In plain English: Baird Medical makes microwave ablation equipment and needles used in China to treat tumors and other growths. The business looks weak today: it is losing money, has weak financial signals, and a very short reporting history. The stock is near its 52-week low and looks very cheap compared with its stated accounting value, but the losses make that cheapness uncertain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer